Breaking News, Collaborations & Alliances

TruTag, Spinnaker in Drug Delivery Partnership

TruTag’s precision nano-porous silica to facilitate Spinnaker’s drug delivery solution

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

TruTag Technologies has entered into a strategic partnership with Spinnaker Biosciences, a biotechnology company focused on the development of proprietary technology for controlled/sustained release drug delivery. TruTag will supply Spinnaker with precision-fabricated nano porous silica particles (pSi).

Founded in 2009, Spinnaker Biosciences is utilizing pSi as a controlled-release drug delivery vehicle. In the Spinnaker solution, active pharmaceutical ingredients (APIs) are loaded into the nanopores of the silica particles. pSi is an ideal candidate for in-vivo drug delivery due to its inherent biocompatibility, biodegradable nature and precision-fabricated particle porosity, which allows for protected storage and sustained delivery of a therapeutic payload.

“TruTag Technologies is recognized as the leader in their field and we are excited to be working with their team,” said Malcolm Finlayson, chief executive officer, Spinnaker Biosciences. “TruTag’s ability to reproducibly manufacture large quantities of GMP pSi to our precise specifications has allowed us to focus resources on building our pipeline and expanding the application of our delivery platform.”

While there are multiple therapeutic areas in which Spinnaker’s pSi can be used, the lead application is in the treatment of neovascular (wet) age-related macular degeneration (ARMD). According to TruTag, the Spinnaker solution offers improved drug delivery to the site of action—the back of the eye—and has a four-month release profile, which improves compliance while reducing the number of injections and the risk of infection.

The initial supply agreement between TruTag and Spinnaker is focused on the provision of pSi in support of Spinnaker’s ARMD clinical program and other third party clinical programs.

“Spinnaker’s drug delivery technology has the potential to be a game-changer that vastly improves therapeutic effectiveness,” said Michael Bartholomeusz, chief executive officer, TruTag Technologies. “We are thrilled to be partnering with Spinnaker as key facilitators of their innovation.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters